Review
Published on 31 Jul 2023
Targeting MCL-1 protein to treat cancer: opportunities and challenges
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1226289
- 15,424 views
- 45 citations
Type at least 3 characters
904 articles
Original Research
Published on 26 Jul 2023
Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1191778
- 2,431 views
- 3 citations
Opinion
Published on 24 Jul 2023
Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1218821
- 2,490 views
- 4 citations
Original Research
Published on 21 Jul 2023
Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1222716
- 4,439 views
- 3 citations
Systematic Review
Published on 20 Jul 2023
Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1176885
- 3,160 views
- 9 citations
Editorial
Published on 20 Jul 2023
Editorial: Anti-cancer drug delivery: lipid-based nanoparticles
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1248272
- 2,740 views
- 1 citation
Original Research
Published on 18 Jul 2023
Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1222411
- 3,641 views
- 7 citations
Review
Published on 14 Jul 2023
A literature review on the impact of disasters on healthcare systems, the role of nursing in disaster management, and strategies for cancer care delivery in disaster-affected populations
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1178092
- 9,961 views
- 9 citations
Original Research
Published on 11 Jul 2023
PIWIL1 interacting RNA piR-017724 inhibits proliferation, invasion, and migration, and inhibits the development of HCC by silencing PLIN3
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1203821
- 2,858 views
- 14 citations
Review
Published on 10 Jul 2023
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1199105
- 12,315 views
- 35 citations
Review
Published on 06 Jul 2023
Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1168454
- 4,846 views
- 6 citations
Review
Published on 04 Jul 2023
Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1204722
- 13,325 views
- 24 citations
Case Report
Published on 03 Jul 2023
Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1199195
- 5,320 views
- 4 citations
Case Report
Published on 30 Jun 2023
Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1167516
- 3,256 views
- 8 citations
Editorial
Published on 26 Jun 2023
Editorial: Novel targeted drugs for indolent lymphoid malignancies
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1224528
- 2,053 views
Editorial
Published on 20 Jun 2023
Editorial: Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer, Volume II
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2023.1218855
- 2,667 views
- 5 citations